A phase I clinical trial of IM-101
Latest Information Update: 13 Mar 2024
At a glance
- Drugs IM-101 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors ImmunAbs
Most Recent Events
- 11 Mar 2024 According to an ImmunAbs media release, the Status changed from planning to completed.
- 11 Mar 2024 According to an ImmunAbs media release, the company announced the successful completion of the Phase 1 clinical trial for IM-101
- 08 Aug 2022 New trial record